Meme Kanserli Hastalarda Neoadjuvan Kemoterapi Öncesi ve Sonrası Periferik Kandaki Eozinofil Hücrelerin Yüzeyinde İfade Edilen Bazı Belirteçlerin Değişimi

Abstract

Neoadjuvant chemotherapy in breast cancer can effect the tumor microenvironment. Eosinophils, which also act as immune cells in the tumor microenvironment, have surface receptors that are responsible for carrying out their functions. Due to the role of eosinophils as immune cells, it is thought that they may play a role in the response to neoadjuvant chemotherapy and can affect clinical outcomes. The aim of this study is to investigate the changes in the expression of certain markers (CD80, CD86, CD274, CD125) on the surface of eosinophil cells in peripheral blood before and after neoadjuvant chemotherapy in breast cancer patients. Additionally, the comparison of eosinophil counts and percentages measured by complete blood count and flow cytometry was also aimed. For this purpose, peripheral venous blood samples were collected from 31 breast cancer patients before neoadjuvant chemotherapy, 43 breast cancer patients after neoadjuvant chemotherapy, and 12 healthy control participants; and the levels of CD80, CD86, CD125, and CD274 markers expressed by eosinophils were measured in complete blood count and flow cytometry. As a result, eosinophil counts and percentages were found to be correlated with each other in both flow cytometry and complete blood count. In addition, levels of CD80 were found to be lower while levels of CD86 were found to be higher in breast cancer patients compared to healthy individuals. These findings were not influenced by neoadjuvant chemotherapy or estrogen receptor expression.